| Ticker: SBTK | 5601 West Howard Street | |
| Exchange: NASDAQ-National Market | Niles, Illinois 60714 | |
| Industry: Manufacturing | (847) 647-2760 |
| Type of Shares: | Common Shares | Filing Date: | 4/22/96 | |
| U.S. Shares: | 2,500,000 | Offer Date: | 6/21/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $11.00 - $13.00 | |
| Primary Shares: | 2,500,000 | Offer Price: | $10.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.70 | |
| Offering Amount: | $30,000,000 | Selling: | $0.42 | |
| Expenses: | $990,000 | Reallowance: | $0.10 | |
| Shares Out After: | 7,679,712 |
| Manager | Tier | Phone |
| Bear, Stearns & Co. Inc. | Lead Manager | (212) 272-2000 |
| Barington Capital Group, L.P. | Co-manager | (212) 974-5722 |
| Salomon Brothers Inc. | Co-manager | (212) 783-2947 |
| Auditor: KPMG Peat Marwick | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $4.04 | $2.94 | $0.93 | Assets: | $6.50 |
| Net Income: | -$6.04 | -$1.72 | -$1.55 | Liabilities: | $8.30 |
| EPS: | -$0.90 | -$0.25 | Equity: | -$1.80 | |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company manufactures multi-therapy infusion systems, including communications technology, designed to meet the needs of the alternate-site health care market. The Company's integrated infusion products incorporate advanced communications technology which is designed to reduce provider operating costs while maintaining the integrity and quality of care. Sabratek's proprietary healthcare information system provides remote programming as well as real-time diagnostic and therapeutic data capture capabilities, allowing care givers to monitor patient compliance more effectively and allowing providers to develop outcome analyses and optimal; clinical protocols. The Company has designed its integrated hardware and software system to permit providers of infusion therapy to achieve cost-effective movement of patients along the continuum of alternate-site health care settings. |
| Use of Proceeds |
| The proceeds from the offering will be used to repay debt, meet obligations under certain stock appreciation rights, expand sales and marketing activities, research and development, increase manufacturing capacity and for working capital and for general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.